Combination Therapy With Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

Vidmantas Petraitis, Ruta Petraitiene, Aspasia Katragkou, Bo Bo Win Maung, Ethan Naing, Povilas Kavaliauskas, Stephen Barat, Katyna Borroto-Esoda, Nkechi Azie, David Angulo, Thomas J Walsh
Antimicrobial Agents and Chemotherapy
May 2020

Pan-resistant Candida Auris Isolates From the Outbreak in New York Are Susceptible to Ibrexafungerp (A Glucan Synthase Inhibitor)

Y C Zhu, S A Barat, K Borroto-Esoda, D Angulo, S Chaturvedi, V Chaturvedi
International Journal of Antimicrobial Agents
April 2020

Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

Annie Lee, Brendan Prideaux, Matthew Zimmerman, Claire Carter, Stephen Barat, David Angulo, Véronique Dartois, David S Perlin, Yanan Zhao
Antimicrobial Agents and Chemotherapy
February 2020

In Vitro Activity of Ibrexafungerp (SCY-078) Against Candida auris Isolates as Determined by EUCAST Methodology and Comparison With Activity Against C. Albicans and C. glabrata and With the Activities of Six Comparator Agents

Maiken Cavling Arendrup, Karin Meinike Jørgensen, Rasmus Krøger Hare, Anuradha Chowdhary
Antimicrobial Agents and Chemotherapy
February 2020

In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor Against Candida Glabrata Isolates With FKS Mutations

Natalie S Nunnally, Kizee A Etienne, David Angulo, Shawn R Lockhart, Elizabeth L Berkow
Antimicrobial Agents and Chemotherapy
October 2019

MSG-10: A Phase 2 Study of Oral Ibrexafungerp (SCY-078) Following Initial Echinocandin Therapy in Non-Neutropenic Patients With Invasive Candidiasis

Andrej Spec, John Pullman, George R Thompson, William G Powderly, Ellis H Tobin, Jose Vazquez, Stephen A Wring, David Angulo, Silvia Helou, Peter G Pappas, Mycoses Study Group
The Journal of Antimicrobial Chemotherapy
October 2019

Activity of a Novel 1,3-beta-D-glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), Against Candida glabrata

M Ghannoum, L Long, N Isham, C Hager, R Wilson, K Borroto-Esoda, S Barat, D Angulo
Antimicrobial Agents and Chemotherapy
September 2019

Ibrexafungerp: A Novel Oral Glucan Synthase Inhibitor

A novel 1,3-beta-D-glucan inhibitor, Ibrexafungerp (formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis

Larkin L, Long L, Isham N, Borroto-Esoda K, Barat S, Angulo D, Ghannoum M
Antimicrobial Agents and Chemotherapy
March 2019

SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [¹⁴C]SCY-078 in Albino and Pigmented Rats.

Wring S, Borroto-Esoda K, Solon E, Angulo D
Antimicrobial Agents and Chemotherapy
January 2019